BioSpace News Archive

Genmab A/S and BioNTech SE announced initial data from the ongoing Phase 2 trial evaluating acasunlimab, an investigational bispecific antibody also known as GEN1046/BNT311, as monotherapy and in combination with pembrolizumab in patients with PD-L-positive metastatic non-small cell lung cancer who had disease progression following one or more prior lines of anti-PD1-containing treatment.

Study shows that FPM data can be reliably and quickly generated even through minimally invasive small-needle biopsies, which may expand the accessibility of FPM to provide personalized treatment validation and recommendations. NIMHD-funded study explores the relationship between biomarkers and racial/ethnic differences in response to cancer therapies to address existing health disparities. New research builds on a body of clinical evidence published in the April issue o

Affimed N.V. announced longer follow-up data from the EGFRwt cohort and initial clinical efficacy data from the EGFRmut cohort from the on-going AFM24-102 study in NSCLC.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced the presentation of updated exploratory subgroup analyses from the SIENDO study, in patients with advanced or recurrent TP53 wild-type endometrial cancer at the 2024 American Society of Clinical Oncology Annual Meeting.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced the presentation of seven studies from its long-acting injectable schizophrenia research program.

Sapience Therapeutics, Inc. presented new clinical and biomarker data from its ST101 Phase 2 study in GBM at the 2024 American Society of Clinical Oncology Annual Meeting.

CStone Pharmaceuticals announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending approval of sugemalimab in combination with chemotherapy as a first-line treatment for metastatic non-small cell lung cancer, which is one of the largest cancer indications and a leading cause of cancer death in the world.

Cullinan Therapeutics, Inc., a biopharmaceutical company focused on developing modality-agnostic targeted therapies, announced positive initial data in patients receiving zipalertinib after prior treatment with amivantamab enrolled in its pivotal Phase 2b REZILIENT1 clinical trial.

Jazz Pharmaceuticals plc announced long-term follow-up results, including the first-ever overall survival findings, from the Phase 2b HERIZON-BTC-01 clinical trial of zanidatamab in previously treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer.

Takeda and Pfizer announced that the German Hodgkin Study Group will present positive results from the Phase 3 HD21 trial evaluating ADCETRIS® in combination with chemotherapy as a late-breaking oral presentation at the 60th American Society of Clinical Oncology Annual Meeting and at the 29th European Hematology Association Annual Meeting.